KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.65

-1.3%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$86.97M
EPS-2.8500
P/E Ratio-2.97
Earnings Date08/12/2026

klrs

Purchases of Investments

Last Annual Value

-34.52M

3-Year CAGR

%

5-Year CAGR

35%

10-Year CAGR

19%

KT

Kalaris Therapeutics Inc Competitors Analysis of Purchases of Investments

KLRS · NASDAQ
CompanyPurchases of Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
-34.52M
N/AN/AN/A 
-91.85M
N/AN/AN/A
-44.88M
N/AN/AN/A
-43.42M
N/AN/AN/A
0.00
N/AN/AN/A
-66.41M
N/AN/AN/A
-101.90M
N/AN/AN/A
-51.59M
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
-88.51M
N/AN/AN/A
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.65, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.65